Evidence map›Paper›PMID 38390706›Full record

ArticleMolecular imaging and radionuclide therapy2024

The Added-value of Staging

Seda Gülbahar Ateş, Bedriye Büşra Demirel, Halil Başar, Gülin Uçmak

Abstract read
In one paragraph

Article in Molecular imaging and radionuclide therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Seda Gülbahar AteşHitit University Çorum Erol Olçok Training and Research Hospital, Department of Nuclear Medicine, Çorum, Türkiye.ORCID 0000-0003-0422-0863
Bedriye Büşra DemirelUniversity of Health Sciences Türkiye, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Clinic of Nuclear Medicine, Ankara, Türkiye.ORCID 0000-0002-6494-062X
Halil BaşarUniversity of Health Sciences Türkiye, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Clinic of Urology, Ankara, Türkiye.ORCID 0000-0003-1770-5165
Gülin UçmakUniversity of Health Sciences Türkiye, Ankara Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Clinic of Nuclear Medicine, Ankara, Türkiye.ORCID 0000-0002-0268-4747

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This retrospective study aimed to evaluate the prognostic importance of Methods: Bladder cancer patients who underwent staging Results: Fifty-five patients [median age: 70 (53-84), 48 (87.3%) male, 7 (12.7%) female] with bladder cancer were included in this study. Twenty-nine (52.7%) patients had Conclusion: The presence of

Indexed as

18F-FDG PET/CTBladder canceroverall survival

Identifiers

PMID38390706
PMCPMC10899737

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.